A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214
Phase 1
Active, not recruiting
- Conditions
- Parkinson's Disease
- Interventions
- Drug: SER-214
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Serina Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT02579473
- Locations
- 🇺🇸
Georgia Regents University, Augusta, Georgia, United States
🇺🇸MD Clinical, Hallandale Beach, Florida, United States
🇺🇸University of Alabama Birmingham, Birmingham, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath